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Summary
 
Cluster of differentation (CD)4
 
1
 
 T helper cells (Th)1s fail to produce interleukin (IL)-4. Even
if restimulated in the presence of IL-4, a condition that induces IL-4–producing capacity in na-
ive CD4
 
1
 
 T cells, Th1s fail to become IL-4 producers. We report that Th1 cells have a major
impairment in IL-4 signaling. When compared to both Th2s and naive T cells, they display a
striking diminution in phosphorylation of Stat6. They also show reduced phosphorylation of
Janus kinase (JAK)-3 and insulin receptor substrate (IRS)-2 when compared to Th2s. Stat6 and
JAK-3 are present in equivalent amounts in Th1s and Th2s, but IRS-2 protein levels are much
lower in Th1s than in Th2s. Altered sensitivity to IL-4, the major inducer of the Th2 pheno-
type, may explain the stability of the Th1 state.
 
N
 
aive CD4
 
1
 
 T cells develop into either of two major
subsets of Ths that produce distinct sets of cytokines.
Th1s generally produce IFN-
 
g
 
, IL-2, and TNF-
 
a
 
, whereas
Th2s produce IL-4, IL-5, IL-10, and IL-13 (1). The polar-
ization of responses to Th1 or Th2 dominance often deter-
mines resistance or susceptibility of hosts to infections and
the degree of tissue damage in many autoimmune diseases
(2–4).
IL-4 is the major determinant of the differentiation of
antigen-stimulated naive cluster of differentiation (CD)
 
1
 
4
 
1
 
T cells into Th2s (5–8). IL-4 mediates its functions through
binding to and stimulation of the IL-4R. The IL-4R con-
sists of the IL-4R
 
a
 
 chain, which binds IL-4 with high affin-
ity (9, 10), and the common gamma chain (
 
g
 
c) (11, 12),
shared by the receptors for IL-2, IL-7, IL-9, and IL-15
(11–15). Upon interaction with IL-4, the IL-4R
 
a
 
 and 
 
g
 
c-
associated kinases, Janus kinase (JAK)-1 and JAK-3, are ac-
tivated (16–18). Both JAK-1 and JAK-3 play critical roles
in IL-4 function. Cell lines expressing JAK-1 mutations fail
to phosphorylate insulin receptor substrate (IRS)-1/2) and
Stat6, two of the major substrates phosphorylated in normal
cells in response to IL-4 (19, 20). T cells from JAK-3–defi-
cient mice show similar defects (21–23).
Mice deficient in IL-4R
 
a
 
 chain (24) or in Stat6 (25–27),
the major regulator of IL-4–mediated gene activation (28),
fail to generate Th2s in vitro and show a marked diminu-
tion in the development of IL-4–producing CD4
 
1
 
 T cells
in response to infection with 
 
Nippostrongylus brasiliensis
 
 (24,
26). Furthermore, Stat6 activation has been mainly impli-
cated in the regulation of IL-4–mediated gene activation.
Thus, Stat6-deficient mice fail to upregulate class II MHC
molecules, CD23, and Thy1 in mouse B cells, and fail to
support class switching to IgE. The major regulators of IL-
4–mediated growth are the phosphotyrosine binding domain
substrates IRS-1/IRS-2 and Shc, whose phosphorylation is
determined by a domain in the IL-4 receptor distinct from
that responsible for Stat6 activation (19, 29–34). However,
thymocytes and B cells from Stat6-deficient mice also dis-
play diminished uptake of [
 
3
 
H] thymidine in response to
IL-4–dependent stimuli (25–27). This may indicate a possi-
ble role for Stat6 in growth regulation; alternatively, a prin-
cipal role of Stat6 may be the induction of factors that are
critical in transmitting growth-inducing signals. Indeed, the
IL-4R
 
a
 
 chain is itself upregulated by IL-4 (9, 35).
Th1s and Th2s differ from one another in several impor-
tant respects. For example, Th1s not only fail to produce
IL-4 when stimulated, but cannot support the transcription
of transfected reporter genes under the control of the IL-4
promoter (36–39). It has recently been demonstrated that
they fail to express 
 
c-maf
 
, a transcription factor that binds to
the IL-4 promoter (40). Transfection of Th1 lines with 
 
c-maf
 
allows them to transcribe reporter genes under the control
of the IL-4 promoter. This transcription is further en-
hanced by the cotransfection of the cDNA for NIP-45, a
protein that interacts with nuclear factor of activated T cells
(41). Furthermore, Th1s fail to express GATA-3, which is
expressed in naive and in Th2s (42). GATA-3 transgenic
mice primed under Th1 conditions (in the absence of IL-4)
can develop into cells capable of inducing IL-4 messenger
RNA (mRNA), indicating an important role for GATA-3
in the differentiation of naive cells into Th2s.
What is particularly striking is that Th1s not only fail to
produce IL-4 upon challenge, but they fail to develop into
IL-4–producing cells even if they are restimulated with an-
tigen in the presence of IL-4 (43–45). These are conditions
 
1
 
Abbreviations used in this paper:
 
 
 
g
 
c, common gamma chain; CD, cluster of
differentiation; EMSA, electrophoretic mobility shift assay; GAS, gamma-
activated sequence; IRS, insulin receptor substrate; JAK, Janus kinase;
mRNA, messenger RNA.
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that cause the development of naive T cells into IL-4 pro-
ducers. Thus, Th1s have lost the ability to induce IL-4–
producing capacity. In addition, it has been reported that
long-term lines of Th1s are incapable of growth in response
to IL-4 despite the fact that Th1 and Th2 lines display es-
sentially equal capacity to bind IL-4 with high affinity (46).
It has been reported that these lines differ in their sensitivity
to IL-1 and it has been suggested that this explains their dif-
ferential sensitivity to IL-4 as a growth stimulus (47).
We wished to examine the possibility that the inability
of Th1s to respond to IL-4 with the induction of IL-4–pro-
ducing activity might reflect an insensitivity of these cells to
IL-4. Here we show that while Th1s express amounts of
IL-4R comparable to Th2s, they lose their capacity to
phosphorylate Stat6 as they differentiate and that such loss
is correlated with the inability of these cells to upregulate
CD30 in response to IL-4 and to develop into IL-4 pro-
ducers. Furthermore, we demonstrate that the level of ex-
pression of IRS-2, a principal regulator of IL-4–mediated
growth, is enhanced upon development of naive cells into
Th2s but not Th1s; this enhancement does not occur in
cells from Stat6-deficient mice. In differentiated Th1s, IL-4
does not enhance expression of IRS-2. These results indi-
cate that a defect in the activation of Stat6 in Th1s can ex-
plain many of the phenotypic properties of these cells.
 
Materials and Methods
 
Animals and Cell Cultures.
 
B10.A mice were obtained from
Jackson Laboratory (Bar Harbor, ME). Mice transgenic for TCR-
 
a
 
and -
 
b
 
 chains encoding a receptor specific for pigeon cytochrome
C peptide 88–104 in association with the IE
 
k
 
 class II MHC mole-
cule were maintained in our animal quarters. Lymph node cells
were depleted of CD8
 
1
 
 cells, B220
 
1
 
 cells, and IA
 
k
 
1
 
 cells by neg-
ative selection using magnetic beads. The purified CD4
 
1
 
 cells
were then centrifuged on a discontinuous 50, 60, and 70% Per-
coll gradient. Cells with a density of 
 
.
 
70% were collected and
used for priming (7). Primary stimulation of TCR transgenic cells
was carried out by culturing 10
 
6
 
 naive CD4
 
1
 
 T cells in the pres-
ence of 10
 
7
 
 irradiated T cell–depleted spleen cells from B10.A, 1 
 
m
 
M
pigeon cytochrome C peptide (prepared by National Institute of
Allergy and Infectious Diseases Biologic Resources Branch) and
IL-2 (10 U/ml) for 7 d. For differentiation of Th1s, monoclonal
anti–IL-4 antibody (11B11; 10 
 
m
 
g/ml) and IL-12 (10 ng/ml)
were also added to the culture; for the differentiation of Th2s, IL-4
(0.5 ng/ml) and anti–IL-12 antibody (R&D Systems, Inc., Min-
neapolis, MN) were added. In some instances, the priming cul-
ture was repeated one or two times. T and B cell–depleted APCs
were prepared from splenocytes by depleting Thy 1.2 and B220
positive cells using the magnetic bead method. Stat6 knockout
mice and littermate controls were provided by Dr. James Ihle (St.
Jude Children’s Research Hospital, Memphis, TN). These (129
 
3
 
 C57BL/6) mice were backcrossed to normal C57BL/6 mice.
 
Immunoprecipitation and Western Blot Analysis.
 
Th1s or Th2s
were washed with HBSS twice, recultured with 10 U/ml rIL-2
overnight, and then deprived of serum and cytokines for 2 h.
Cells (5 
 
3
 
 10
 
6
 
 ml) were stimulated with 5 ng/ml of IL-4 in com-
plete RMPI at room temperature for 12 min. The reaction was
stopped with cold PBS containing 100 
 
m
 
M Na
 
3
 
 VO
 
4
 
. Cells were
then lysed with 0.5 ml lysis buffer (50 mM Hepes, 0.5% Nonidet
P-40, 5 mM EDTA, 50 mM NaCl, 10 mM Na pyrophosphate,
and 50 mM NaF) freshly supplemented with 1 mM Na
 
3
 
 VO
 
4
 
, 1 mM
PMSF, and 10 
 
m
 
g/ml aprotinin, leupeptin, and pepstatin. Lysates
were incubated with 5–10 
 
m
 
l antibody for 2 h on ice. Immune
complexes were precipitated with protein G agarose beads (Pierce
Chemical Co., Rockford, IL), eluted with SDS-PAGE loading
buffer, separated in a 7.5% acrylamide gel, and transferred onto
Immobilon-P membranes (Millipore, Bedford, MA), which were
probed with specific antibodies (17) and visualized with an en-
hanced chemiluminescent detection system (Pierce Chemical
Co.). Anti-Stat6 antibody was provided by Dr. James Ihle (St.
Jude Children’s Research Hospital, Memphis, TN), anti–JAK-3
by Dr. John O’Shea (National Institutes of Health, Bethesda, MD),
and anti–IRS-2 antibody and anti–phosphotyrosine (4G10) were
purchased from Upstate Biotechnology Inc. (Lake Placid, NY)
 
Reverse Transcriptase PCR.
 
TCR transgenic Th2s were washed
extensively at the end of the priming culture and recultured in
IL-2 supplemented complete medium for 14 d until these cells
had become small and round shaped. These well-“rested” cells
(10
 
6
 
) were then either unstimulated or stimulated with 2 
 
3
 
 10
 
5
 
irradiated T and B cell–depleted APCs, IL-2, and cytochrome C
peptide with or without IL-4 (0.5 ng/ml) for 6 or 22 h. Total
RNA were prepared by the guanidinium method and reverse
transcribed into cDNA. PCRs were performed using IRS-2
primers (forward: TGGTGAGGCAGGTACCCGTCT; reverse:
TCTGCACGGATGACCTTAGCA; reference 48) and actin
primers (forward: GATGACGATATCGCTGCGCTG; reverse:
GTACGACCAGAGGCATACAGG). Amplification was per-
formed (geneAmp PCR system 9600; Perkin-Elmer Corp., Foster
City, CA). The cycling conditions were 94
 
8
 
C for 15 s, 59
 
8
 
C for
15 s, and 72
 
8
 
C for 30 s for 35 cycles, followed by extension at
72
 
8
 
C for 5 min. PCR products were analyzed by electrophoresis
in a 2% agarose gel.
 
Flow Cytometry Analysis and ELISA.
 
For IL-4R staining, cells
were incubated with 10% goat serum for 5 min to block nonspe-
cific binding. M1 anti–IL-4R monoclonal antibody or a rat iso-
type control (Genzyme, Cambridge, MA) were added to the cells
and incubated for 20 min in FACS
 
Ò
 
 buffer (Becton Dickinson,
Mountain View, CA; PBS/3% fetal calf serum/0.1% sodium
azide). Cells then were washed with FACS
 
Ò
 
 buffer. FITC-labeled
goat Fab
 
9 
 
fragment against rat IgG (Southern Biotechnology As-
sociates, Birmingham, AL) were added to stained cells for 20 min.
For CD30 staining, cells were first blocked with 10 
 
m
 
l of 2.4G2
rat anti–mouse Fc
 
g
 
RII/III ascitic fluid for 5 min before staining
with PE-labeled monoclonal antibody against mouse CD30
(PharMingen, San Diego, CA) for 20 min in FACS
 
Ò
 
 buffer. The
stained cells were washed twice with FACS
 
Ò
 
 buffer and analyzed
in a FACScan
 
Ò
 
. IL-4 and IFN-
 
a
 
 production were measured us-
ing commercial ELISA detection kits (Endogen, Woburn, MA).
 
Results
 
Th1 Cells Display a Marked Diminution in IL-4–induced
Stat6 and JAK-3 Phosphorylation.
 
We prepared dense CD4
 
1
 
T cells from mice transgenic for TCR-
 
a
 
 and -
 
b
 
 chains spe-
cific for a cytochrome C peptide in association with IE
 
k
 
(7). These cells were primed in vitro by culturing for two
rounds of 7 d each with T cell–depleted spleen cells from
B10.A mice together with 1 
 
m
 
M cytochrome C peptide
and IL-2. To generate Th1s, we added monoclonal anti–
IL-4 antibody and IL-12; to generate Th2s, we added IL-4
and anti–IL-12 antibody. Extracts prepared from Th2s that 
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had been stimulated with IL-4 for 12 min were immuno-
precipitated with anti-Stat6. When analyzed by SDS-
PAGE and Western blotting with antiphosphotyrosine, we
observed striking tyrosine phosphorylation of Stat6. By
contrast, immunoprecipitates of extracts from IL-4–stimu-
lated Th1s showed no detectable Stat6 phosphorylation.
Western blots with anti-Stat6 antibody revealed compara-
ble amounts of Stat6 in both Th1s and Th2s (Fig. 1 
 
A
 
).
Naive CD4
 
1
 
 T cells respond to IL-4 with Stat6 phos-
phorylation comparable to that observed for Th2s (Fig. 1
 
B
 
). Unstimulated cells expressed no detectable phosphory-
lation. The degree of such IL-4–induced phosphorylation
remains stable in the course of priming CD4
 
1
 
 T cells with
cytochrome C peptide, APCs, IL-2, IL-4, and anti–IL-12
(i.e. to the Th2 phenotype). When cells are primed with
anti–IL-4 and –IL-12 (i.e., to the Th1 phenotype), IL-4–
induced Stat6 phosphorylation remains detectable during
the initial round of priming (i.e., at 3 d). Stat6 phosphory-
lation is sometimes completely lost by the end of the first
round of priming, but in most experiments (as illustrated
in Fig. 1 
 
B
 
), IL-4–induced Stat6 phosphorylation is not lost
in Th1s until two rounds of priming.
IL-4–induced phosphorylation of JAK-3 was also dimin-
ished in “two-round” primed Th1s (Fig. 1 
 
A
 
). The relative
degree of phosphorylation of JAK-3 in Th1s was reduced
by 
 
z
 
3.7-fold compared to Th2s. The amount of JAK-3
protein in Th1s was no different than the amount in com-
parably primed Th2s. The diminution in IL-4–induced
JAK-3 phosphorylation in Th1s did not reflect a general-
ized inactivation of this kinase or of the 
 
g
 
c chain in Th1s
since IL-2 caused striking phosphorylation of JAK-3 in
these cells (Fig. 1 
 
A
 
). This is particularly important since
IL-2 signaling, like IL-4 signaling, uses both JAK-1 and
JAK-3.
 
Th1s and Th2s Have Comparable Numbers of IL-4Rs.
 
The defect that Th1s show in IL-4–induced signaling could
not be explained by the failure of these cells to express IL-
4Rs. Two-round–primed Th1s and Th2s from transgenic
donors displayed comparable numbers of IL-4Rs as dem-
onstrated by flow cytometric analysis with the anti–mouse
IL-4R antibody M1; the specificity and high affinity bind-
ing of IL-4 was established by the capacity of IL-4 (1.1 
 
3
 
10
 
2
 
10
 
M) to inhibit binding by both cell types (Fig. 2 
 
A
 
).
Indeed, in four independent experiments, the relative de-
gree of expression of IL-4Rs by Th1s was 1.01 
 
6
 
 0.14 that
of Th2s (Fig. 2 
 
B
 
). In contrast to naive T cells, IL-4 does
not further upregulate IL-4R expression in recently primed
Th1s or Th2s (data not shown).
Figure 1. Impaired IL-4–induced phosphorylation of Stat6 and JAK-3
in Th1s. (A) Two-round–primed TCR transgenic Th1s and Th2s were
recultured in IL-2 for 1 d and then deprived of serum and cytokines for 2 h.
Cells (2.5 3 107) were stimulated with IL-4 (5 ng/ml) or with IL-2 (100
U/ml) in separate experiments for 12 min. Cell lysates were incubated
with anti-Stat6 or anti–JAK-3 antibody and precipitated with protein G/
agarose beads. Phosphorylated Stat6 or JAK-3 was detected by blotting
with antiphosphotyrosine antibody (aPY). The same filter was stripped
and reprobed with anti-Stat6 or anti–JAK-3 antibody. (B) Lysates were
prepared from TCR transgenic cells that had been stimulated under Th1
or Th2 conditions for 3 d, for one round of 7 d, or for two rounds of 7 d
each. B10.A CD41 lymph node cells (Unprimed) were treated with or
without IL-4, lysed, and analyzed for Stat6 phosphorylation and content.
Figure 2. IL-4R expression in Th1s and Th2s. (A) 105 two-round–
primed TCR transgenic Th1s and Th2s were incubated with the M1
anti–IL-4R monoclonal antibody or a rat isotype control in the presence
or absence of IL-4 (1.5 ng/ml). The cells were washed and stained with
FITC-labeled Fab goat anti–rat IgG. Samples were analyzed with a FAC-
SCANÒ. (B) To calculate the ratio of IL-4R expression in Th1s and
Th2s, the mean fluorescence intensity (MFI) of M1-stained Th1s minus
the MFI of isotype control Th1s was divided by the MFI of M1-stained
Th2s minus the MFI of isotype control Th2s. 
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Th1s Have Diminished Expression of IRS-2.
 
To get a fuller
picture of the signaling abnormality of IL-4Rs in Th1s, we
examined the phosphorylation of a molecule that has been
implicated in IL-4–mediated growth, IRS-2. Fig. 3 dem-
onstrates that IL-4–induced phosphorylation of IRS-2 is
strikingly diminished in Th1s compared to Th2s. How-
ever, in contrast to Stat6 and JAK-3, which are present in
similar amounts in Th1s and Th2s, the level of expression
of IRS-2 protein, as detected by immunoblotting of anti–
IRS-2 immunoprecipitates, is markedly diminished in Th1s
compared to Th2s. Furthermore, although Stat6 is present
in relatively similar amounts in unprimed CD4
 
1
 
 T cells, in
Th1s and Th2s, IRS-2 is present in very limited amounts in
unprimed cells (Fig. 4 
 
A
 
). The sustained induction of IRS-2
expression in Th2s appears to be Stat6 dependent. Thus, when
CD4
 
1
 
 T cells from Stat6-deficient mice are primed with solu-
ble anti-CD3, anti-CD28, APCs, IL-2, IL-4, and anti–IL-12
for one round, they fail to express detectable IRS-2, whereas
littermate heterozygotes show induction of IRS-2 under
Th2- but not Th1-priming conditions (Fig. 4 
 
B
 
).
An analysis of the induction of IRS-2 protein using
CD4
 
1
 
 T cells from TCR transgenic donors in the course
of priming with cytochrome C peptide reveals that cells
primed in the Th1 and Th2 “directions” both initially in-
duce IRS-2 (i.e., at 3 d), but IRS-2 is only sustained in the
cells primed in the presence of IL-4, so that by 5 d of prim-
ing, cells primed under Th1 conditions have less IRS-2
than do cells primed under Th2 conditions (Fig. 5). There-
after, IRS-2 levels in Th1s are lower than in Th2s, particu-
Figure 3. Th1s possess less IRS-2 and display less IRS-2 phosphoryla-
tion in response to IL-4. Two-round–primed TCR transgenic Th1s or
Th2s (2.5 3 107) were stimulated with or without IL-4 for 12 min. Ly-
sates were prepared and immunoprecipitated with anti–IRS-2 or anti-
Stat6 antibody and analyzed for phosphorylation and content.
Figure 4. Induction of IRS-2 protein is Stat6 dependent. (A) Lysates
prepared from B10.A CD41 lymph node T cells or from two-round–
primed TCR transgenic Th1s or Th2s were immunoprecipitated with
anti–IRS-2 or anti-Stat6 antibody. The amount of IRS-2 and Stat6 pro-
tein was determined by Western blot analysis using anti–IRS-2 or anti-
Stat6 antibody. (B) Naive CD41 T cells, prepared from lymph nodes of
Stat6-deficient mice or their heterozygous littermates, were primed (one
round) with 3 mg/ml soluble anti-CD3 and anti-CD28 under Th1 or
Th2 conditions. The amount of IRS-2 protein was determined by immu-
noprecipitation and Western blot analysis using anti–IRS-2 antibody.
Figure 5. Upregulation of
IRS-2 expression and IL-4–in-
duced phosphorylation of IRS-2
during the course of Th2 devel-
opment. Lysates were prepared
from purified TCR transgenic
lymph node CD41 (Unprimed) or
TCR transgenic lymph node
CD41 cells that were stimulated
with T and B cell–depleted APCs,
cytochrome C, and IL-2 under
either Th1 or Th2 conditions for
3, 5, or 7 d, or for two rounds of
7 d each. IRS-2 phosphorylation
and content was analyzed by im-
munoprecipitation with anti–
IRS-2 antibody and Western
blot analysis using antiphospho-
tyrosine or anti–IRS-2 antibody.
Lysates were prepared from equal
numbers of cells.
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larly by 2 wk of priming. The levels of phosphorylation of
IRS-2 in Th1s are also strikingly diminished compared to
Th2s from 5 d of priming and after (Fig. 5).
Th1s not only fail to express substantial amounts of IRS-2,
they fail to show stable induction of IRS-2 when restimu-
lated for 7 d in the presence of cytochrome C peptide,
APC, IL-2, IL-4, and anti–IL-12 (Th2-inducing condi-
tions; Fig. 6 A). Thus, in fully primed Th1s, IL-4 does not
appear to be able to induce stable expression of IRS-2, in
keeping with the “desensitization” of the IL-4R in these
cells. Interestingly, Th2s restimulated for 7 d in Th1-inducing
conditions continue to express IRS-2, although possibly at
somewhat lower levels than Th2s that have been restimu-
lated in Th2 conditions. Indeed, IRS-2 expression in Th2s
is not entirely stable. If Th2s are rested by culture in IL-2
for 14 d, their expression of IRS-2 falls markedly. Upon
stimulation with cytochrome C peptide and APC without
IL-4, they show a transient induction of IRS-2 mRNA
(Fig. 6 B). By contrast, if IL-4 is included in the culture,
IRS-2 mRNA expression is more sustained, indicating the
importance of IL-4 in regulating IRS-2 expression in Th2s.
Failure of Th1s to Respond to IL-4 Correlates with the Lack
of IL-4–dependent Upregulation of CD30. To examine fur-
ther whether the diminished Stat6 phosphorylation in-
duced by IL-4 in Th1s correlated with a failure to upregu-
late IL-4–dependent molecules, we examined the capacity
of IL-4 to enhance expression of CD30 (49) in Th1s and
Th2s. Naive C57BL/6 CD41 T cells were primed with
soluble anti-CD3 and anti-CD28 with irradiated APCs un-
der Th1 or Th2 conditions for two rounds of 7 d each.
They were then stimulated for 3 d with anti-CD3, anti-
CD28, and irradiated APCs with IL-4 or anti-IL–4. A sub-
set of Th2 cells from C57BL/6 donors stimulated in the
presence of IL-4 show induction of CD30 at 3 d (Fig. 7),
whereas stimulation of these cells in the presence of anti–
IL-4 failed to induce CD30. Th1s from C57BL/6 mice
failed to induce CD30 when challenged in the presence of
IL-4 or of anti–IL-4.
Similarly, as we and others have previously reported (43–
45), “twice-primed” TCR transgenic Th1s fail to develop
the capacity to produce IL-4 even if restimulated with cy-
tochrome C peptide, APC, IL-2, and IL-4 for 7 d (Fig. 8).
Discussion
Our results show that as naive CD41 T cells differentiate
to the Th1 phenotype, a major impairment of signaling
through the IL-4R occurs. This is most apparent in the de-
gree of induced phosphorylation of Stat6, which is the
principal regulator of IL-4–mediated gene activation. The
level of activation of JAK-3 is also impaired, whereas dif-
ferences in degree of expression of the IL-4R are minimal.
This result could explain the stability of the Th1 pheno-
type. The molecular basis of this impaired sensitivity of the
IL-4R in Th1 cells is not known. The decreased phosphor-
ylation of JAK-3 and the presence of normal amounts of
Stat6 and JAK-3 protein suggest that it may reflect an over-
all effect in the receptor signaling activity rather than a spe-
Figure 6. Failure of culture under Th2 conditions to induce IRS-2 ex-
pression in well-differentiated Th1s. (A) Two-round–primed TCR trans-
genic Th1s or Th2s were restimulated with cytochrome C plus irradiated
APCs under Th1 (1 . 1; 2 . 1) or Th2 (1 . 2; 2 . 2 ) conditions for 7 d.
IRS-2 and Stat6 protein content were determined by immunoprecipita-
tion and Western blot analysis using anti–IRS-2 and anti-Stat6 antibody. (B)
Well-rested two-round–primed TCR transgenic Th2s left unstimulated
(i.e., treated with anti–IL-4), stimulated with IL-4 alone, or stimulated
with irradiated T and B cell–depleted spleen cells, cytochrome C peptide,
IL-2, and anti–IL-4 or IL-4 for 6 h and 22 h. Total RNAs were prepared
with RNAzol and reverse transcribed into cDNA. PCR was performed
with IRS-2 or actin primers. Products were analyzed in 2% agarose gel. 
Figure 7. Failure of Th1s to respond to Th2 conditions with elevated
expression of CD30 or production of IL-4. CD41 lymph node T cells
from C57BL/6 cells were primed for two rounds with anti-CD3, anti-
CD28, T-depleted irradiated APCs, and IL-2 under Th1 or Th2 condi-
tions. They were then restimulated with anti-CD3, anti-CD28, T-depleted
irradiated APCs, and IL-2 in the presence of IL-4 or anti–IL-4 for 3 d.
CD30 expression was determined by FACSÒ analysis using PE-labeled
anti-CD30 antibody after the 3-d culture. The brackets delimit the area of
fluorescence of unstained cells.1310 Impaired IL-4 Signaling in Th1s
cific effect on Stat6. The capacity of IL-2 to induce JAK-3
phosphorylation in Th1s indicates that the defect is not
specific for JAK-3 and the gc chain. In light of the recent
discovery of a new family of cytokine-induced JAK/STAT
inhibitors (50–53), it is conceivable that during the devel-
opment of Th1s one or more such inhibitors are induced
and prevent JAK-3/Stat6–dependent IL-4–mediated sig-
naling in these cells. However, we have not observed any
difference in levels of expression of mRNA for SOCS 2
(suppressor of cytokine signaling 2) in Th1s and Th2s; we
could not detect expression of SOCS 1 or 3 in Th1s or
Th2s, although we could detect these mRNAs in bone
marrow cells treated with IFN-a and IL-3 for 1 h (Huang, H.,
unpublished data).
It is also striking that IL-4 regulates the level of expres-
sion of IRS-2 in recently differentiated Ths. Naive T cells
display very low levels of IRS-2 protein and mRNA. Ini-
tial stimulation with antigen and APC causes a transient in-
duction of IRS-2, which is only sustained in the presence
of IL-4. Thus, Th1s that have been stimulated through two
rounds of priming display little or no IRS-2, whereas Th2s
that have been primed for two rounds show substantial
amounts of IRS-2 and vigorous phosphorylation in re-
sponse to IL-4 stimulation.
The diminished sensitivity of Th1s to IL-4–mediated
signaling may explain the failure of upregulation of IRS-2
in these cells. The regulation of IRS-2 expression by IL-4
and particularly the failure of Stat6 knockout cells to show
such a response might also explain the diminished IL-4–
stimulated growth of thymocytes from Stat6-deficient mice
(25–27). These cells should fail to respond to IL-4 with en-
hanced expression of IRS-2 and IL-4Rs, since both are
controlled by the IL-4/Stat6 signaling pathway; low levels
of both IL-4R and IRS-2 might then limit IL-4 induced
growth.
Kubo et al. (54) have recently reported that a Th1 T cell
clone and a hybridoma with a Th1 phenotype failed to
phosphorylate Stat6 in response to IL-4. Thus, the lack of
IL-4–mediated signaling by Th1 cells is likely to be a very
stable property of these cells. Kubo et al. (53) argue that
Th1s fail to secrete IL-4 because of a silencer element lo-
cated 39 of exon 4 of the IL-4 gene that contains a Stat6-
binding site. They further argue that Stat6 binding to this
site inactivates the silencer element and thus allows IL-4 to
be made in response to phorbol ester and ionomycin stim-
ulation. Thus, the failure of Th1s to produce IL-4 is ex-
plained by the lack of activated Stat6 in these cells, whereas
the capacity of Th2s to secrete IL-4 depends upon the acti-
vation of Stat6 and the consequent blocking of silencer
function. Although this concept has attractive features, our
previous results (55) have shown that once naive T cells
have been differentiated into Th2s, IL-4 is no longer re-
quired for the production of IL-4 or other Th2 cytokines
by these cells. Thus, Th2s stimulated with antigen and
APC produce IL-4 mRNA in the presence of neutralizing
concentrations of anti–IL-4 or anti–IL-4R antibody. Fur-
thermore, IL-4 does not enhance IL-4 production by these
cells even when limiting concentrations of antigen are used
for stimulation. Finally, Th2s prepared from IL-4 knockout
mice produce normal amounts of IL-13 mRNA in re-
sponse to stimulation with anti-CD3; IL-4 does not en-
hance production of IL-13 by these differentiated Th2s.
Our results, indicating a failure of recently differentiated
Th1s to phosphorylate Stat6, and those of Kubo et al. (53)
describing absent Stat6 phosphorylation in a Th1 clone and
a Th1 hybridoma, contrast with results that have been de-
scribed showing that extracts from IL-4–stimulated Th1s
can form complexes with a gamma-activated sequence
(GAS) element as detected by electrophoretic mobility shift
analysis (EMSA). Szabo et al. (56) and Lederer et al. (57)
observed an IL-4–inducible EMSA in cultures that had
been differentiated in the Th1 direction for one round of
stimulation; cells from such cultures retained the capacity
to develop IL-4–producing activity if cultured for an addi-
tional 4–7 d with antigen and IL-4. Indeed, it was subse-
quently demonstrated that cells that had been primed in the
Th1 direction for several rounds lost the capacity to de-
velop into IL-4–producing cells (43), consistent with our
observation that IL-4–induced phosphorylation of Stat6 is
often not extinguished until cells have undergone two
rounds of Th1 priming. Pernis et al. (58) reported that in a
Th1 clone (AE.7), IL-4 induced a factor (then designated
STF–IL-4) that formed a complex with the GAS element
from FcgR1. The significance of this finding remains to be
evaluated further. This could be explained by differences
among individual long-term Th1-like clones and recently
differentiated Th1s. Alternatively, the IL-4R may retain
some signaling properties in Th1s that nonetheless do not
allow full activation of Stat6. Indeed, EMSA often reveals
Figure 8. Th1s fail to acquire IL-4–producing capacity even if cultured
under Th2 conditions. Two-round–primed TCR transgenic Th1s were
restimulated under Th1 or Th2 conditions for 7 d; similarly primed Th2
cells were restimulated under Th2 conditions for 7 d. At the end of cul-
ture, cells were washed extensively. 106 washed cells were restimulated
with cytochrome C peptide plus 106 irradiated spleen cells for 24 h. Su-
pernatants were assayed for IFN-g and IL-4 by ELISA. B.D. below de-
tection.1311 Huang and Paul
that IL-4 induces multiple bands containing the GAS ele-
ment, only one of which is supershifted by anti–Stat6 anti-
body.
Understanding the molecular basis of the diminished
sensitivity of IL-4Rs in well-differentiated Th1s might pro-
vide interesting targets for the development of agents that
could reverse the polarity of these cells. Such agents could
be important in the development of strategies for treatment
of tissue damaging autoimmunity or to reverse inappropri-
ate responses to certain pathogenic agents.
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